The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.
The company is collating data on physician decision-making from early-access users, and believes that it can make a strong case for clinical utility of the test.
Rome-based Resnova will distribute Empire's FISH probes and molecular diagnostic services in Italy.
The Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata research hospital in Rome will perform SelectMDx testing locally.
The company offers a range of tumor profiling products including the OncoDeep solid tumor test and the OncoTrace liquid biopsy test.
Danish IVD firm BioPorto will distribute a version of its NGAL Test for use on the Cobas c 501/
Launch Diagnostics will distribute BioGx's entire product line, including laboratory-use-only products, in the UK and Ireland.
AxonLab will distribute BioGx's entire product line, including laboratory-use-only products, in central European countries.
AmoyDx's molecular diagnostics tests, powered by its ADx-ARMS and Super-ARMS technologies, will be made available in Hong Kong and Macau.
Genext will market and distribute OncoDNA's line of tumor profiling products and services including its liquid biopsy tests.